John P. Jakupciak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John P. Jakupciak has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Catherine D. O'COnnell
Tetracore, Inc., Gaithersburg, MD 20878, USA
2 shared publicationsDonald H. Atha
Biochemical Science Division, National Institute of Standards and Technology, 100 Bureau Drive, MS 8311, 20899, Gaithersburg, MD, USA
2 shared publicationsWendy Wang
Cancer Biomarkers Research Group, National Cancer Institute, Rockville, MD, USA
2 shared publicationsAnirban Maitra
The Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publicationBrenna M. McGruder
Biochemical Science Division, National Institute of Standards and Technology, 100 Bureau Drive, MS 8311, 20899, Gaithersburg, MD, USA
1 shared publication- Christian C. Abnet
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1 shared publication
Latest Publications
- 1 December 2006
- Vol. 8 (6) , 500-6
Analysis of potential cancer biomarkers in mitochondrial DNA.
Understanding mitochondrial biology is a fundamental research goal in human genetics and medicine. The use of mitochondria to serve as a biomarker is rapidly expanding in disciplines ranging from cancer, rare metabolic diseases, aging, the tracing of human migration patterns in antiquity, population characterization using maternal markers, and human identification. Mitochondrial DNA (mtDNA) mutations occur frequently in cancer, and there is an important need for validating mtDNA mutations as cancer biomarkers for the detection of early-stage disease. Although a few studies have suggested tissue-specific mtDNA mutations, there is no single mutational hotspot associated with the wide spectrum of cancer patients; hence, sequencing the entire mitochondrial genome and further characterization of the multiple deletions associated with tumors is required to detect the mutation load on an individual basis. Microarray-based technology provides a reliable and rapid method to detect all mutations of the entire mitochondrial genome. In addition to microarray-based sequencing, real-time PCR is an important method for deletion analysis. Mutations throughout the mitochondrial genome are recurrent events in primary tumor tissues and in corresponding non-invasively collected body fluids. Thus, mtDNA mutation analysis may provide a molecular tool for the early detection and prognosis of cancer. Recent findings have verified that relatively simple diagnostic tests for detecting mtDNA mutations, involving mitochondrial microarray chips and/or real-time PCR bioassays, have exciting predictive potential for cancer detection and prognosis.
- 1 December 2006
- Vol. 8 (6) , 500-6
Analysis of potential cancer biomarkers in mitochondrial DNA.
Understanding mitochondrial biology is a fundamental research goal in human genetics and medicine. The use of mitochondria to serve as a biomarker is rapidly expanding in disciplines ranging from cancer, rare metabolic diseases, aging, the tracing of human migration patterns in antiquity, population characterization using maternal markers, and human identification. Mitochondrial DNA (mtDNA) mutations occur frequently in cancer, and there is an important need for validating mtDNA mutations as cancer biomarkers for the detection of early-stage disease. Although a few studies have suggested tissue-specific mtDNA mutations, there is no single mutational hotspot associated with the wide spectrum of cancer patients; hence, sequencing the entire mitochondrial genome and further characterization of the multiple deletions associated with tumors is required to detect the mutation load on an individual basis. Microarray-based technology provides a reliable and rapid method to detect all mutations of the entire mitochondrial genome. In addition to microarray-based sequencing, real-time PCR is an important method for deletion analysis. Mutations throughout the mitochondrial genome are recurrent events in primary tumor tissues and in corresponding non-invasively collected body fluids. Thus, mtDNA mutation analysis may provide a molecular tool for the early detection and prognosis of cancer. Recent findings have verified that relatively simple diagnostic tests for detecting mtDNA mutations, involving mitochondrial microarray chips and/or real-time PCR bioassays, have exciting predictive potential for cancer detection and prognosis.
- 28 November 2006
- Published by Elsevier in Cancer Letters
- Vol. 244 (1) , 91-100
Real-time telomerase assay of less-invasively collected esophageal cell samples
- 28 November 2006
- Published by Elsevier in Cancer Letters
- Vol. 244 (1) , 91-100
Real-time telomerase assay of less-invasively collected esophageal cell samples
- 1 November 2005
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 1 (4-5) , 233-239
Standards for validation of cancer biomarkers
As large scale genomics and proteomics efforts identify an increasingly complex list of biomarkers to identify human disease, populations predictive for that disease, and drug or other therapy responses for treatment, attention is needed in the resea
- 1 November 2005
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 1 (4-5) , 233-239
Standards for validation of cancer biomarkers
As large scale genomics and proteomics efforts identify an increasingly complex list of biomarkers to identify human disease, populations predictive for that disease, and drug or other therapy responses for treatment, attention is needed in the resea
- 1 September 2005
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 5 (5) , 745-753
Real-time telomerase activity measurements for detection of cancer
Since the hallmark report of the PCR-based telomeric repeat amplification protocol (TRAP) in 1994, there has been a flurry of investigations of telomerase activity on normal, benign, premalignant and cancerous samples representative of the various stages of tumorigenesis. Basic research and technological advances in human genetics, biochemistry and model systems have brought much progress towards the understanding of human infectious, hereditary and somatically acquired diseases. The knowledge of carcinogenesis has increased very rapidly in the past few years, particularly with the development of automated molecular biologic analysis of tumors and preneoplastic lesions. Despite the wide variety of studies on the potential use of telomerase as a cancer biomarker, the variability of reported telomerase activity and the lack of a transferable detection method have prevented it from becoming a routine clinical application. Real-time PCR is a clinically transferable method and the advancement of real-time measurements of telomerase will facilitate moving telomerase activity and technologies towards clinical validation. It is expected that the next 5 years will see telomerase integrated into the initial detection and follow-up monitoring of cancer patients. The hope is that the use of telomerase will finally translate into a diagnostic to help realize longer survival and a better quality of life.
- 1 September 2005
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 5 (5) , 745-753
Real-time telomerase activity measurements for detection of cancer
Since the hallmark report of the PCR-based telomeric repeat amplification protocol (TRAP) in 1994, there has been a flurry of investigations of telomerase activity on normal, benign, premalignant and cancerous samples representative of the various stages of tumorigenesis. Basic research and technological advances in human genetics, biochemistry and model systems have brought much progress towards the understanding of human infectious, hereditary and somatically acquired diseases. The knowledge of carcinogenesis has increased very rapidly in the past few years, particularly with the development of automated molecular biologic analysis of tumors and preneoplastic lesions. Despite the wide variety of studies on the potential use of telomerase as a cancer biomarker, the variability of reported telomerase activity and the lack of a transferable detection method have prevented it from becoming a routine clinical application. Real-time PCR is a clinically transferable method and the advancement of real-time measurements of telomerase will facilitate moving telomerase activity and technologies towards clinical validation. It is expected that the next 5 years will see telomerase integrated into the initial detection and follow-up monitoring of cancer patients. The hope is that the use of telomerase will finally translate into a diagnostic to help realize longer survival and a better quality of life.
- 1 May 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (2) , 258-267
Mitochondrial DNA as a Cancer Biomarker
- 1 May 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (2) , 258-267
Mitochondrial DNA as a Cancer Biomarker